Serplulimab versus placebo plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Efficacy and safety from the end-of-study analysis of the international phase 3 ASTRUM-005 study.

Authors: Ying Cheng, Liang Han, Lin Wu, Jun Chen, Hongmei Sun, Guilan Wen, Yinghua Ji, Anastasia V. Zimina, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Tamar Melkadze, Yueyin Pan, Xuhong Min, Maksym Viguro, Jing Li, Qingyu Wang, Jun Zhu,

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.8093

Source: Full article

---

Abstract

8093